Hudson Bay Capital Management
ICPT

Hudson Bay Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Hudson Bay Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-75,200
Closed -$4.37M – 566
2017
Q3 		$4.37M Buy
+75,200
New +$8.1M 0.11% 160

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Hudson Bay Capital Management's ICPT Position: Q2 2020 in Review

Hudson Bay Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2020, closing a stake of 50,000 shares — an estimated $3.15M sold.

Hudson Bay Capital Management first reported a position in ICPT in Q3 2014 and held it in 5 quarters. The position peaked at $4.73M in Q3 2014. 192 funds tracked by Wall St. Rank hold ICPT as of Q2 2020.

  • Hudson Bay Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 50,000 Intercept Pharmaceuticals, Inc. shares in Q2 2020, an estimated $3.15M.
  • Hudson Bay Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 5 quarters.
  • Hudson Bay Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $4.73M in Q3 2014.
  • 192 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2020.

Based on Hudson Bay Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.